Rebecca Gardner

TL;DR: This review covers the development of CAR T cells for B-ALL, citing the remarkable efficacy of inducing remissions in a very high-risk population of patients and the identification of targets beyond CD19.

TL;DR: This research presents a novel, scalable, scalable and scalable approach that aims to improve the quality of life of children undergoing bone Marrow Transplantation and Cellular Therapy in the United States.

TL;DR: The experience using CAR T cell immunotherapy for patients with R/R infant ALL enrolled on clinical trials PLAT-02 andPLAT-05 is reported, with results indicating small patient size, heavily pre-treated disease and high leukemia burden are often characteristics of this subgroup of patients that pose unique challenges to apheresis and manufacture of a T cell product.

TL;DR: A case of iAMP21 that does not fit the formal FISH definition is presented, demonstrating that CMA is helpful for the detection of this entity when FISH results are ambiguous and showing that RUNX1 is not the primary target of amplification.

TL;DR: This paper conducted a prospective observational study of the humoral immunogenicity of commercially available 2019-2020 inactivated influenza vaccines in adults immediately prior to or while in durable remission after CAR-T-cell therapy, as well as controls.